{"filing":{"accession_number":"0001104659-26-088393","cik":"0001379006","ticker":"NNVC","company_name":"NANOVIRICIDES, INC.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-24","primary_document":"tm2621493d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1379006/000110465926088393/tm2621493d1_8k.htm"},"events":[{"id":21910,"run_id":19778,"accession_number":"0001104659-26-088393","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"NanoViricides completed a registered direct offering on July 27, 2026, selling 2,416,339 shares of common stock at $1.53 per share, pre-funded warrants, and common warrants to purchase 2,516,339 additional shares for approximately $3.8 million in gross proceeds. The offering was announced on July 24, 2026, pursuant to an effective Form S-3 shelf registration statement and includes a 60-day lock-up on further issuances.","company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":21683,"accession_number":"0001104659-26-088393","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"NanoViricides entered into a securities purchase agreement on July 24, 2026, to sell 2,416,339 shares of common stock at $1.53 per share, pre-funded warrants, and common warrants to purchase 2,516,339 additional shares in a registered direct offering generating approximately $3.8 million in gross proceeds. This is a classic dilutive equity issuance—a registered direct offering of common stock and warrants that increases share count and dilutes existing shareholders. The transaction closed on July 27, 2026, and the company imposed a 60-day lock-up on further issuances, consistent with typical PIPE/registered direct offering structures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T10:09:52.382647+00:00","company_name":"","ticker":null,"filing_date":""},{"id":21684,"accession_number":"0001104659-26-088393","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company announced pricing of a registered direct offering of approximately 2.5 million shares of common stock (or pre-funded warrants) together with accompanying warrants for gross proceeds of ~$3.8 million. This is a registered equity issuance that will dilute existing shareholders. The press release explicitly states the offering is pursuant to an effective Form S-3 shelf registration statement, and the shares are being sold in combination with warrants, which is characteristic of a dilutive capital raise by a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T10:09:52.382647+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21683,"accession_number":"0001104659-26-088393","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"NanoViricides entered into a securities purchase agreement on July 24, 2026, to sell 2,416,339 shares of common stock at $1.53 per share, pre-funded warrants, and common warrants to purchase 2,516,339 additional shares in a registered direct offering generating approximately $3.8 million in gross proceeds. This is a classic dilutive equity issuance—a registered direct offering of common stock and warrants that increases share count and dilutes existing shareholders. The transaction closed on July 27, 2026, and the company imposed a 60-day lock-up on further issuances, consistent with typical PIPE/registered direct offering structures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T10:09:52.382647+00:00","company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","filing_date":"2026-07-30"},{"id":21684,"accession_number":"0001104659-26-088393","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company announced pricing of a registered direct offering of approximately 2.5 million shares of common stock (or pre-funded warrants) together with accompanying warrants for gross proceeds of ~$3.8 million. This is a registered equity issuance that will dilute existing shareholders. The press release explicitly states the offering is pursuant to an effective Form S-3 shelf registration statement, and the shares are being sold in combination with warrants, which is characteristic of a dilutive capital raise by a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T10:09:52.382647+00:00","company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","filing_date":"2026-07-30"}]}